European Lifestars Awards - Celebrating Life Science Leaders’ Post

Out now: the updated 'MS Brain Health – time matters' report was launched at ECTRIMS yesterday! It highlights the importance of early diagnosis, timely treatment and holistic, person-centred care, along with the policy changes needed to improve long-term outcomes for those living with MS, NMOSD and MOGAD. #BrainHealthTM #BrainHealth #MSTimeMatters

Our new #BrainHealthTimeMatters is now available: https://lnkd.in/eDavWAg So many have made this work possible. Our thanks go to Alexion Pharma Germany GmbH and Merck Healthcare for sponsoring the launch of this report and helping bring this work to all; to Roche, MS Society and Horizon, now part of Amgen for their critical support towards the development of the report; to the panel of authors Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, Giancarlo Comi, Kathy Costello, Michael Devlin, Jelena Drulovic, Emma Gray, Jodi Haartsen, Anne Helme, Jana Hlaváčová, Elisabeth Kasilingam, Yaou Liu, Thomas Mathew, Saul Reyes, Jérôme de Sèze and Mitzi Joi Williams M.D., FAAN and to the many members of the Working Groups named in the report who brought expertise and evidence to shape and support the recommendations. We thank you and look forward the next steps - collaborating with you and further stakeholders to support the implementation of the recommendations. #BrainHealthTM #BrainHealth #MSTimeMatters, #NMOSDTimeMatters, #MOGADTimeMatters, #MSBH #OHPF, The Sumaira Foundation, Sumaira Ahmed, EMSP - European Multiple Sclerosis Platform, MS International Federation (MSIF), Can Do MS

Agreed, the patient-centric approach is so important when it comes to treatments.

Well done Doug Lavender and Timothy Kilchenmann for organising such an insightful and inspirational event! And thank you for giving me the opportunity to be an active contributor this year. A few highlights from this 7th annual digital biomarkers in clinical trials summit : - the promise of precision psychiatry through digital phenotyping - mapping of 700+ speech variables: building blocks of novel endpoints in CNS - predictive/safety monitoring BMs for better oncology treatment outcomes - hormonal impact on Parkinson’s disease symptoms: inclusive research matters! - « digital paradox » in clinical research - nocturnal scratch DE validation journey continues under tech company’s leadership with DECODE - platform like DEEP: new WoW to simplify DE development, validation & qualification And some important reminders on best practices for DE development: - start with the why! What problem are you trying to solve? - if you want to go far, go together! And place the patient at the center of your collaboration. - engage regulators early on your validation plans.

Marinomed Biotech AG announces results for the first quarter of 2024 · Revenues for the first quarter 2024 declined to pre-pandemic levels of EUR 0.7 million driven by high customer stock levels and return of seasonality · Q1 2024: New partnerships for Carragelose and Solv4U, agreement with financing partners for deferral of repayments and progress with P&G for the U.S. · Several initiatives for both Marinosolv and Carragelose assets to generate sufficient cash flows covering the Company’s financing needs “In the first quarter of 2024, we reported good progress for our Carragelose business: Two new distribution partnerships, positive clinical data for blocking allergens as well as the start of a clinical study for our moisturizing eye drops. After the reporting period, we saw the launch in Mexico as well as the first launch for the new allergy blocker in Austria. Regarding our partnership with Procter & Gamble, we are waiting for feedback from the FDA that would allow the launch of our product in the upcoming season”, Andreas Grassauer, CEO of Marinomed, mentions. “Furthermore, we concluded the second long-term partnership for Solv4U with Aché. After solving stability issues for our product candidates Budesolv and Tacrosolv, we are now also making good progress with our Marinosolv products in negotiations with potential partners and the conclusion of partnerships is closer than ever.” 📰 The full press release is available here: https://lnkd.in/dcPsgaTd 📈 The financial report is available here: https://lnkd.in/dbDwyePA #q1results #quaterlyresults #investorrelations #oceanofideas #Carragelose #Marinosolv #Solv4U #partnerships #Budesolv #Tacrosolv

As the population of the US continues to diversify, creating an inclusive healthcare environment will become even more crucial. Join Dr Taylor and myself as we review some practical tips that you can incorporate into your everyday clinical practice to ensure each person feels welcome and recognized for their own unique selves! #diversity #inclusivity #breakingbarriers

Today marks a significant milestone in our mission to create an accessible and diverse clinical trial ecosystem. EQBMED proudly welcomes Amgen and Merck as our inaugural sponsors. Amgen and Merck will co-design and pilot strategies—such as enhancing infrastructure, increasing trial capacity, and providing support to overcome barriers like travel and transportation—to foster closer engagement with local EQBMED trial sites and communities. This collaboration is key to improving medical research by bringing local trial sites, communities, and sponsors together as partners. https://lnkd.in/er4uYQEN

Quick tricks to improve patient care!

A huge congratulations to Sujal Shah, a respected colleague and friend, who announced this week a sale of CymaBay Therapeutics to Gilead Sciences for an impressive $4.3 billion, or $32.50 per share. The deal is a testament to Sujal’s relentless pursuit of innovation and excellence.   Behind the accolades lies a journey filled with intense challenges and unwavering dedication. In 2019, during clinical trials for Seladelpar targeting NASH and PBC, Cymabay encountered unexpected atypical histological findings, leading to a full clinical hold. The impact was not just financial, with the stock price crashing to a little over a dollar, but also deeply personal, requiring some very tough decisions and affecting the morale and spirit of everyone involved.   Sujal's leadership during these trying times was nothing short of remarkable. Steering the company through adversity, he maintained focus on the mission, and was ultimately able to demonstrate that the findings were unrelated to Seladelpar, clearing the path for continued clinical development.   The journey of drug development is fraught with obstacles and setbacks, yet it's the resilience, perseverance, and collective effort of teams like Cymabay's that pave the way for breakthrough therapies capable of transforming lives.   As we celebrate this achievement, it’s important to remember the hard work, determination, spirit of collaboration, and some luck, that make such successes possible. Hats off to Sujal Shah and the entire Cymabay team for their exceptional contribution to the field of medicine.   $CBAY  #Biotech #M&A #Leadership #Resilience #carnegiemellon Carnegie Mellon University - Tepper School of Business  

It's webinar season at Norstella and we are hosting several open events to talk through our recent research reports and views of the industry. No speaking duties for me, but having seen snippets from each then I'm looking forward to making myself comfortable in the audience. Great opportunities to stay abreast of industry trends – whether your focus is in drug development, market access, or somewhere in between – and to get closer to the subject matter experts behind our brands. 💡 Pharma R&D Annual Review: May 21, 3pm BST/10am ET Ian Lloyd and Alexandra Shimmings, both of Citeline, continue their long-standing double act in reviewing the latest global R&D trends. Pipelines, approvals, emerging modalities, therapeutic areas, drug targets, leading sponsors, geographic hotspots and more - if you've seen any of the previous editions then you know not to miss this. https://lnkd.in/efECkPtd 💡 Overcoming the Barriers to Patient Access in 2024 and Beyond: May 21, 7pm BST/2pm ET If you are more focused on the latest commercial dynamics, then join Dinesh Kannan Kabaleeswaran and Jennifer (Goldenberg) Klarer, M.Sc.Eng. in this review of the latest patient access themes. MMIT (Managed Markets Insight & Technology) and The Dedham Group joined forces earlier in the year for a quantitative stakeholder survey, and this is our exclusive take on the results and implications for patient access, from pharma to payers and providers. https://lnkd.in/eTkwBerh 💡 Orphan Drugs - Are They Losing Their Sparkle: May 29, 3pm BST/10am ET Puru Gaur will give the lowdown from Evaluate Ltd's latest orphan drug deep dive, with Melanie Senior and Stephanie Leouzon debating the implications of an apparent slow down in sales growth. Does this indicate a drop in investor and pharma appetite for rare diseases, or is it just a case of maturity. And how do new technologies and legislation affect the balance? Join us to find out. https://lnkd.in/e_he3TQu